Waldenstrom Macroglobulinemia - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 214 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Waldenstrom Macroglobulinemia - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Waldenstrom Macroglobulinemia - Pipeline Review, H1 2016', provides an overview of the Waldenstrom Macroglobulinemia pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Waldenstrom Macroglobulinemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Waldenstrom Macroglobulinemia and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Waldenstrom Macroglobulinemia
- The report reviews pipeline therapeutics for Waldenstrom Macroglobulinemia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Waldenstrom Macroglobulinemia therapeutics and enlists all their major and minor projects
- The report assesses Waldenstrom Macroglobulinemia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Waldenstrom Macroglobulinemia

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Waldenstrom Macroglobulinemia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Waldenstrom Macroglobulinemia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Content 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Waldenstrom Macroglobulinemia Overview 9
Therapeutics Development 10
Pipeline Products for Waldenstrom Macroglobulinemia - Overview 10
Waldenstrom Macroglobulinemia - Therapeutics under Development by Companies 11
Waldenstrom Macroglobulinemia - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Waldenstrom Macroglobulinemia - Products under Development by Companies 16
Waldenstrom Macroglobulinemia - Companies Involved in Therapeutics Development 18
AbbVie Inc. 18
Amgen Inc. 19
arGEN-X BV 20
Aurigene Discovery Technologies Limited 21
Bayer AG 22
BeiGene, Ltd. 23
Calithera Biosciences, Inc. 24
Celgene Corporation 25
Genentech, Inc. 26
Gilead Sciences, Inc. 27
Hutchison MediPharma Limited 28
Idera Pharmaceuticals, Inc. 29
IGF Oncology, LLC. 30
Incyte Corporation 31
Juno Therapeutics Inc. 32
Karyopharm Therapeutics, Inc. 33
Merck KGaA 34
Millennium Pharmaceuticals, Inc. 35
Novartis AG 36
Takeda Pharmaceutical Company Limited 37
Vivolux AB 38
Waldenstrom Macroglobulinemia - Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Combination Products 40
Assessment by Target 41
Assessment by Mechanism of Action 44
Assessment by Route of Administration 46
Assessment by Molecule Type 48
Drug Profiles 50
(INCB-039110 + INCB-040093) - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
765IGF-MTX - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
acalabrutinib - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
alisertib - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
ARGX-110 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
BGB-3111 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
bortezomib - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
CA-4948 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
carfilzomib - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
CB-839 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
copanlisib hydrochloride - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
DI-B4 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
entospletinib - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
everolimus - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
HMPL-523 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
IMO-8400 - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
INCB-40093 - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
INCB-50465 - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
itacitinib adipate - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
ixazomib citrate - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
JCAR-015 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
lenalidomide - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
ofatumumab - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
oprozomib - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 113
selinexor - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
Small Molecules to Inhibit IRAK4 for Immunology and Oncology - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
spebrutinib besylate - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
venetoclax - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
VLX-1570 - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
Waldenstrom Macroglobulinemia - Recent Pipeline Updates 130
Waldenstrom Macroglobulinemia - Dormant Projects 207
Waldenstrom Macroglobulinemia - Discontinued Products 208
Waldenstrom Macroglobulinemia - Product Development Milestones 209
Featured News & Press Releases 209
May 27, 2015: Amgen To present data from Oprozomib study at the 20th Congress of the EHA 209
Nov 07, 2013: Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations On Oprozomib at 55th American Society of Hematology Annual Meeting 209
Apr 01, 2013: Onyx Pharma To Present Data On Oprozomib At 14th International Myeloma Workshop 210
Nov 06, 2012: Onyx Pharma Announces Data Presentations On Oprozomib At 54th American Society Of Hematology Annual Meeting 211
Nov 08, 2011: Genmab To Present Data On Ofatumumab At 53rd American Society Of Hematology Annual Meeting And Exposition 211
Appendix 213
Methodology 213
Coverage 213
Secondary Research 213
Primary Research 213
Expert Panel Validation 213
Contact Us 213
Disclaimer 214

List of Tables

Number of Products under Development for Waldenstrom Macroglobulinemia, H1 2016 10
Number of Products under Development by Companies, H1 2016 12
Comparative Analysis by Late Stage Development, H1 2016 13
Comparative Analysis by Clinical Stage Development, H1 2016 14
Comparative Analysis by Early Stage Development, H1 2016 15
Products under Development by Companies, H1 2016 16
Products under Development by Companies, H1 2016 (Contd..1) 17
Waldenstrom Macroglobulinemia - Pipeline by AbbVie Inc., H1 2016 18
Waldenstrom Macroglobulinemia - Pipeline by Amgen Inc., H1 2016 19
Waldenstrom Macroglobulinemia - Pipeline by arGEN-X BV, H1 2016 20
Waldenstrom Macroglobulinemia - Pipeline by Aurigene Discovery Technologies Limited, H1 2016 21
Waldenstrom Macroglobulinemia - Pipeline by Bayer AG, H1 2016 22
Waldenstrom Macroglobulinemia - Pipeline by BeiGene, Ltd., H1 2016 23
Waldenstrom Macroglobulinemia - Pipeline by Calithera Biosciences, Inc., H1 2016 24
Waldenstrom Macroglobulinemia - Pipeline by Celgene Corporation, H1 2016 25
Waldenstrom Macroglobulinemia - Pipeline by Genentech, Inc., H1 2016 26
Waldenstrom Macroglobulinemia - Pipeline by Gilead Sciences, Inc., H1 2016 27
Waldenstrom Macroglobulinemia - Pipeline by Hutchison MediPharma Limited, H1 2016 28
Waldenstrom Macroglobulinemia - Pipeline by Idera Pharmaceuticals, Inc., H1 2016 29
Waldenstrom Macroglobulinemia - Pipeline by IGF Oncology, LLC., H1 2016 30
Waldenstrom Macroglobulinemia - Pipeline by Incyte Corporation, H1 2016 31
Waldenstrom Macroglobulinemia - Pipeline by Juno Therapeutics Inc., H1 2016 32
Waldenstrom Macroglobulinemia - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 33
Waldenstrom Macroglobulinemia - Pipeline by Merck KGaA, H1 2016 34
Waldenstrom Macroglobulinemia - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 35
Waldenstrom Macroglobulinemia - Pipeline by Novartis AG, H1 2016 36
Waldenstrom Macroglobulinemia - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 37
Waldenstrom Macroglobulinemia - Pipeline by Vivolux AB, H1 2016 38
Assessment by Monotherapy Products, H1 2016 39
Assessment by Combination Products, H1 2016 40
Number of Products by Stage and Target, H1 2016 42
Number of Products by Stage and Mechanism of Action, H1 2016 45
Number of Products by Stage and Route of Administration, H1 2016 47
Number of Products by Stage and Molecule Type, H1 2016 49
Waldenstrom Macroglobulinemia Therapeutics - Recent Pipeline Updates, H1 2016 130
Waldenstrom Macroglobulinemia - Dormant Projects, H1 2016 207
Waldenstrom Macroglobulinemia - Discontinued Products, H1 2016 208